Key result
Embolization with the liquid embolic agent Onyx successfully treated an iatrogenic common iliac artery pseudoaneurysm and persistent type 1 endoleak, with no recurrence at 1-year follow-up.
Why the study?
Iatrogenic common iliac artery pseudoaneurysms carry a high rupture risk, and ineffective stent graft sealing can cause type I endoleaks requiring bailout solutions.
Case Report (n=1)
No
Onyx liquid embolic agent may serve as an effective bailout solution for type 1 endoleaks following stent graft implantation for iatrogenic common iliac artery pseudoaneurysms.
Onyx may be considered in rare bailout scenarios; this Level 5 case leaves open its reliability for type 1 endoleaks.
A 68-year-old male patient with a history of femoro-femoral bypass following unsuccessful intervention for chronic total iliac occlusion was found to have a saccular pseudoaneurysm of the right common iliac artery (CIA) due to interventional device-related injuries associated with the past endovascular intervention. An iatrogenic pseudoaneurysm in the CIA is generally asymptomatic, but it has a high risk of rupture, regardless of its size or symptoms. Endovascular therapy may be the best treatment option; however, ineffective sealing with a stent graft may lead to a type I endoleak. Under such conditions, use of the liquid embolic agent, Onyx, as a bailout solution for the type 1 endoleak is promising.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) conducted a case report in Iatrogenic common iliac artery pseudoaneurysm and persistent type 1 endoleak (n=1). Onyx liquid embolic agent was evaluated on Resolution of endoleak and pseudoaneurysm. Embolization with the liquid embolic agent Onyx successfully treated an iatrogenic common iliac artery pseudoaneurysm and persistent type 1 endoleak, with no recurrence at 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: